UBS AM’s Kezar Life Sciences KZR Stock Holding History

UBS AM’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,623	Closed	-$82.1K	–	2649
2023 Q2	$82.1K	Hold	2,623	–	–	﹤0.01%	2649
2023 Q1	$82.1K	Buy	+2,623	New	+$152K	﹤0.01%	2649
2022 Q4	–	Sell	-1,002	Closed	-$86.2K	–	2647
2022 Q3	$86.2K	Buy	+1,002	New	+$97.3K	﹤0.01%	2698

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS AM's KZR Position: Q3 2023 in Review

UBS AM sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 2,623 shares — an estimated $82.1K sold.

UBS AM first reported a position in KZR in Q3 2022 and held it in 3 quarters. The position peaked at $86.2K in Q3 2022. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

UBS AM reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
UBS AM sold 2,623 Kezar Life Sciences shares in Q3 2023, an estimated $82.1K.
UBS AM first reported a position in Kezar Life Sciences in Q3 2022 and held it in 3 quarters.
UBS AM's Kezar Life Sciences position peaked at $86.2K in Q3 2022.
82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.